Printer Friendly

FDA publishes dietary supplement AER guidance.

On December 26th, FDA published a guidance to reflect its current thinking with regard to reporting serious adverse events for dietary supplements. This draft guidance document is intended to assist the dietary supplement industry in complying with the labeling requirements prescribed for dietary supplement manufacturers, packers, and distributors by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (Pub. L. 109-462, 120 Stat. 3469). The full guidance document can be accessed at

The draft guidance covers the following topics:

(1) What "domestic address" means for purposes of the dietary supplement labeling requirements in section 403(y) of the Federal Food, Drug, and Cosmetic Act (FFD & C Act);

(2) FDA's recommendation for the use of an introductory statement before the domestic address or phone number that is required to appear on the product label under section 403(y); and

(3) When FDA intends to begin enforcing the labeling requirements of section 403(y).

COPYRIGHT 2008 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:TOP OF THE NEWS
Publication:Nutraceuticals World
Date:Mar 1, 2008
Previous Article:CRN to educate pharmacists about dietary supplements.
Next Article:Dannon being sued for misleading claims.

Related Articles
Dietary Supplement GMPs: what with all the added complexity? Examining FDA's proposed rule for dietary supplements reveals hidden details, which may...
Herbal lottery: what's on a dietary supplement's label may not be what's in the bottle.
LSRO releases report on monitoring adverse events related to dietary supplements.
Dietary supplement GMPs to be released in December.
New dietary supplement cGMP regulations unveiled.
How solid is your substantiation? FDA has released a new guidance that reflects its current thinking on how it reviews evidence for health claims.
AHPA urges FDA to provide guidance on new laws & regulations.
Does the evidence support the claim? As FDA ramps up enforcement in food and dietary supplements, companies need to know what claims can be made for...
FDA estimates substantiation burden for dietary supplements.
AHPA seeks marketing clarification for OTC drug/supplement products.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |